| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-80 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-12 |
| filingDate |
2004-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51b24ef938837748cbc25e3ab781ded3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60dee06ed4f22120f641ed3b23ca355a |
| publicationDate |
2005-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005009903-A1 |
| titleOfInvention |
CB2-selective cannabinoid analogues |
| abstract |
Cannabinoid analogues that exhibit specificity for the CB 2 cannabinoid receptor are provided. The analogues are 1-methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Δ 8 -tetrahydrocannabinols and 1-alkyl-3(1-naphthoyl)indoles. The compounds are useful for the treatment of pain (especially pain resulting from inflammation) and cancer (especially glioma tumors). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112661739-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10369131-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9801849-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9820964-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012024670-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10085964-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105228613-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10154986-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11052066-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9034895-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3997095-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014127016-A3 |
| priorityDate |
2003-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |